Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Capital Expenditures (2016 - 2025)

International Stem Cell (ISCO) has disclosed Capital Expenditures for 15 consecutive years, with $3000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures fell 91.89% to $3000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $41000.0, a 75.15% decrease, with the full-year FY2024 number at $166000.0, up 107.5% from a year prior.
  • Capital Expenditures was $3000.0 for Q3 2025 at International Stem Cell, down from $32000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $126000.0 in Q2 2024 to a low of $1000.0 in Q4 2024.
  • A 4-year average of $26909.1 and a median of $14000.0 in 2023 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: skyrocketed 164.29% in 2024, then plummeted 91.89% in 2025.
  • International Stem Cell's Capital Expenditures stood at $10000.0 in 2021, then skyrocketed by 40.0% to $14000.0 in 2023, then crashed by 92.86% to $1000.0 in 2024, then surged by 200.0% to $3000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Capital Expenditures are $3000.0 (Q3 2025), $32000.0 (Q2 2025), and $5000.0 (Q1 2025).